RSV Specific Neutra™ Antibody Products
Product listAre prolonged therapeutic development timelines or inefficient neutralization assays hindering your RSV research? Creative Biolabs' RSV specific Neutra™ antibody products overcome these challenges with advanced epitope mapping and high-affinity designs, enabling precise targeting of viral entry mechanisms to accelerate therapeutic discovery and diagnostic innovation.
Introduction to RSV
Respiratory syncytial virus (RSV), a member of the Pneumoviridae family, is a non-segmented, negative-sense RNA virus responsible for acute respiratory tract infections. It predominantly affects infants, older adults, and immunocompromised individuals, with seasonal outbreaks causing significant global morbidity and mortality. The virus exhibits two antigenic subtypes (RSV-A and RSV-B), both leveraging host cell machinery to replicate and propagate infection.
- Structural Features
RSV virions are enveloped particles (150–250 nm) featuring three surface glycoproteins:
- Fusion (F) protein: Mediates viral entry by fusing host and viral membranes. Pre- and post-fusion conformations dictate infectivity, making F a primary target for neutralizing antibodies.
- Attachment (G) protein: Facilitates viral binding to host cell receptors, including CX3CR1 and heparan sulfate proteoglycans.
- Small hydrophobic (SH) protein: Modulates host immune responses and viral pathogenicity.
- Host Signaling Pathways
RSV infection dysregulates critical immune pathways, such as:
- TLR4/NF-κB: Activation drives inflammatory cytokine production, contributing to bronchiolitis and pneumonia.
- JAK/STAT: Suppressed by viral non-structural proteins (e.g., NS1/NS2), attenuating interferon-mediated antiviral responses.
- PI3K/Akt: Promotes viral replication by delaying apoptosis in infected cells.
Fig.1 Interferon signaling pathway altered by non-structural proteins.1
- Associated Pathologies
RSV is the leading cause of hospitalization in infants under six months, with symptoms ranging from mild upper respiratory tract infections to severe bronchiolitis and pneumonia. In adults, RSV exacerbates chronic cardiopulmonary diseases and causes substantial mortality in elderly populations.
Clinical Applications of RSV Neutralizing Antibodies
- Therapeutic Intervention in Acute Infection
High-affinity neutralizing antibodies reduce viral load and mitigate symptom severity in hospitalized patients. Administered early, they shorten recovery time and minimize complications like respiratory failure.
- Prophylaxis for High-Risk Populations
Pre-exposure antibody administration protects immunocompromised individuals and preterm infants, reducing RSV-associated hospitalization by up to 70% in clinical trials.
- Maternal Immunization Strategies
Transplacental antibody transfer from vaccinated mothers to neonates confers passive immunity, decreasing infant RSV incidence during the first six months of life.
- Outbreak Control in Healthcare Settings
Rapid serological testing using anti-F antibodies identifies asymptomatic carriers, enabling timely isolation to curb nosocomial transmission.
Our Anti-RSV Neutralizing Antibodies
Neutralizing antibodies targeting RSV F protein have revolutionized therapeutic and prophylactic strategies. These antibodies bind to antigenic sites Ø and V on the F protein's prefusion conformation, blocking membrane fusion and viral entry. Critical applications include:
- Diagnostic development: Quantifying viral load in clinical samples.
- Therapeutic intervention: Reducing hospitalization rates in high-risk populations.
- Vaccine evaluation: Validating epitope-specific immune responses in preclinical models.
Creative Biolabs' anti-RSV antibodies exhibit unmatched specificity (>95% binding affinity validation) and batch-to-batch consistency, supporting reproducible outcomes in ELISA, flow cytometry, and neutralization assays.
Creative Biolabs' RSV specific Neutra™ antibody portfolio offers rigorously validated tools for researchers and developers aiming to outpace RSV's clinical burden. Engineered for superior sensitivity and reproducibility, our antibodies empower breakthroughs in therapeutic discovery, vaccine development, and rapid diagnostics.
Contact our team today to discuss customized solutions for your RSV projects.
REFERENCE
- Thornhill, Elena Margaret, and David Verhoeven. "Respiratory syncytial virus's non-structural proteins: masters of interference." Frontiers in cellular and infection microbiology 10 (2020): 225. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcimb.2020.00225
